Jochen H. Lorch

10.4k total citations · 4 hit papers
121 papers, 5.4k citations indexed

About

Jochen H. Lorch is a scholar working on Oncology, Otorhinolaryngology and Surgery. According to data from OpenAlex, Jochen H. Lorch has authored 121 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 41 papers in Otorhinolaryngology and 31 papers in Surgery. Recurrent topics in Jochen H. Lorch's work include Head and Neck Cancer Studies (41 papers), Thyroid Cancer Diagnosis and Treatment (27 papers) and Salivary Gland Tumors Diagnosis and Treatment (15 papers). Jochen H. Lorch is often cited by papers focused on Head and Neck Cancer Studies (41 papers), Thyroid Cancer Diagnosis and Treatment (27 papers) and Salivary Gland Tumors Diagnosis and Treatment (15 papers). Jochen H. Lorch collaborates with scholars based in United States, France and Germany. Jochen H. Lorch's co-authors include Robert I. Haddad, Marshall R. Posner, Nicholas J. Sarlis, Roy B. Tishler, Glenn J. Hanna, Olga Goloubeva, Kevin J. Cullen, Isaac Brownell, Sandra P. D’Angelo and Shailender Bhatia and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Jochen H. Lorch

114 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

2016 933 citations Jochen H. Lorch et al. profile →
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

2013 486 citations Robert I. Haddad, Guilherme Rabinowits et al. profile →
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial

2011 353 citations Marshall R. Posner, Jochen H. Lorch et al. profile →
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial

2011 310 citations Jochen H. Lorch, Olga Goloubeva et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jochen H. Lorch United States	32	2.9k	1.8k	1.5k	1.0k	948	121	5.4k
Glenn J. Hanna United States	26	1.4k 0.5×	756 0.4×	522 0.3×	591 0.6×	582 0.6×	149	2.6k
Renata Ferrarotto United States	33	2.7k 0.9×	694 0.4×	1.6k 1.0×	933 0.9×	975 1.0×	210	4.7k
Jonathan D. Schoenfeld United States	32	2.6k 0.9×	660 0.4×	735 0.5×	644 0.6×	1.2k 1.2×	139	4.1k
B Luboïnski France	40	1.9k 0.7×	3.2k 1.8×	3.0k 1.9×	620 0.6×	1.8k 1.9×	136	6.0k
Kazuhiko Ogawa Japan	39	1.3k 0.5×	376 0.2×	1.2k 0.8×	1.2k 1.2×	2.0k 2.2×	320	5.7k
W.H. Lau China	34	2.7k 0.9×	2.2k 1.2×	1.9k 1.2×	493 0.5×	1.0k 1.1×	63	5.3k
Amanda Psyrri Greece	48	3.7k 1.3×	2.1k 1.2×	1.4k 0.9×	2.5k 2.4×	1.7k 1.7×	251	7.2k
Jaana Hagström Finland	33	1.5k 0.5×	901 0.5×	1.1k 0.7×	1.2k 1.2×	544 0.6×	228	4.1k
Guilherme Rabinowits United States	21	1.2k 0.4×	662 0.4×	492 0.3×	1.4k 1.3×	514 0.5×	71	3.1k
Francisco Civantos United States	43	1.2k 0.4×	796 0.4×	1.9k 1.3×	498 0.5×	1.9k 2.0×	136	4.8k

Countries citing papers authored by Jochen H. Lorch

Since Specialization

Citations

This map shows the geographic impact of Jochen H. Lorch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jochen H. Lorch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jochen H. Lorch more than expected).

Fields of papers citing papers by Jochen H. Lorch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jochen H. Lorch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jochen H. Lorch. The network helps show where Jochen H. Lorch may publish in the future.

Co-authorship network of co-authors of Jochen H. Lorch

This figure shows the co-authorship network connecting the top 25 collaborators of Jochen H. Lorch. A scholar is included among the top collaborators of Jochen H. Lorch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jochen H. Lorch. Jochen H. Lorch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gennaro, Nicolò, Amir A. Borhani, Linda C. Kelahan, et al.. (2025). Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer. Tomography. 11(3). 20–20.

Lorch, Jochen H., et al.. (2025). Primary cutaneous neuroendocrine tumour of the scalp with metastasis. BMJ Case Reports. 18(6). e263869–e263869.

Goliaei, Bahram, Amir Reza Aref, Jochen H. Lorch, et al.. (2022). Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. Cells. 11(22). 3534–3534. 3 indexed citations

Wan, Zhengpeng, Shun Zhang, Mark F. Coughlin, et al.. (2022). A Robust Method for Perfusable Microvascular Network Formation In Vitro. Small Methods. 6(6). e2200143–e2200143. 39 indexed citations

Παππά, Θεοδώρα, Sara Ahmadi, Ellen Marqusee, et al.. (2021). Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients. Clinical Cancer Research. 27(15). 4256–4264. 33 indexed citations

Kuo, Lindsay E., Justine A. Barletta, Jonathan D. Schoenfeld, et al.. (2021). NUT Carcinoma of the Thyroid: An Unusual Case with a Complete Response to Treatment. Clinical Thyroidology. 33(1). 38–47. 6 indexed citations

Pasternak, Jesse D., Trevor E. Angell, & Jochen H. Lorch. (2021). Nihilism No More: The 2021 ATA Anaplastic Thyroid Cancer Guidelines. Clinical Thyroidology. 33(5). 229–233. 1 indexed citations

Lorch, Jochen H.. (2020). The 2020 American Society of Clinical Oncology Conference: Exciting New Data on Thyroid Cancer. Clinical Thyroidology. 32(7). 347–350. 1 indexed citations

Kumar, Vivek, Atul B. Shinagare, Helmut G. Rennke, et al.. (2020). The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. The Oncologist. 25(6). 505–514. 104 indexed citations

10.

Hanna, Glenn J., Jochen H. Lorch, Robert I. Haddad, et al.. (2020). The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. The Oncologist. 25(7). 598–608. 29 indexed citations

11.

Wong, Kristine, Fei Dong, Milhan Telatar, et al.. (2020). Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. Thyroid. 31(6). 933–940. 51 indexed citations

12.

Lorch, Jochen H.. (2019). ASCO 2019 — What's New in Thyroid Oncology?. Clinical Thyroidology. 31(7). 269–271.

13.

Wong, Kristine, Jochen H. Lorch, Erik K. Alexander, et al.. (2019). Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. Thyroid. 29(5). 666–673. 22 indexed citations

14.

Wong, Kristine, Jochen H. Lorch, Erik K. Alexander, et al.. (2019). Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. Thyroid. 29(9). 1255–1261. 34 indexed citations

15.

Chau, Nicole G., Yvonne Y. Li, Vickie Y. Jo, et al.. (2016). Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 22(12). 2939–2949. 39 indexed citations

16.

Li, Yvonne Y., Glenn J. Hanna, Alvaro C. Laga, et al.. (2015). Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma. Clinical Cancer Research. 21(6). 1447–1456. 208 indexed citations

17.

Fogg, Mark H., John R. Murphy, Jochen H. Lorch, Marshall R. Posner, & Fred Wang. (2013). Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein–Barr virus associated nasopharyngeal carcinoma. Virology. 441(2). 107–113. 25 indexed citations

18.

Lin, Chi‐Iou, Edward E. Whang, David B. Donner, et al.. (2010). Autophagy Induction with RAD001 Enhances Chemosensitivity and Radiosensitivity through Met Inhibition in Papillary Thyroid Cancer. Molecular Cancer Research. 8(9). 1217–1226. 95 indexed citations

19.

Posner, Marshall R., Lisa M. Schumaker, Ming Tan, et al.. (2009). Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients. Cancer Prevention Research. 2(9). 776–781. 221 indexed citations

20.

Lorch, Jochen H., Tarita O. Thomas, & Hans‐Joachim Schmoll. (2007). Bortezomib Inhibits Cell-Cell Adhesion and Cell Migration and Enhances Epidermal Growth Factor Receptor Inhibitor–Induced Cell Death in Squamous Cell Cancer. Cancer Research. 67(2). 727–734. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact